GlassScriptPhysician profile
Rajat Dhar
NPI 1649298191
$30,767.39
in general payments reported to CMS, 2019-2025
12 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $110 · 2021: $13.95 · 2022: $1,412 · 2023: $9,173 · 2024: $1,600 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,318 · Food and Beverage: $1,485 · Travel and Lodging: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,317.50 |
| Food and Beverage | $1,485.35 |
| Travel and Lodging | $1,172.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $18,565.22 | 2019-2024 | Briviact |
| Immedica Pharma US, INC. | $9,710.56 | 2022-2023 | |
| Ceribell, INC. | $1,137.50 | 2024 | Pocket Eeg Device |
| Cumberland Pharmaceuticals, INC. | $928.86 | 2019-2025 | Caldolor, Vibativ |
| La Jolla Pharmaceutical Company | $125.89 | 2023 | Giapreza |
| Haemonetics Corporation | $101.73 | 2024 | Ensoetm |
| Bard Access Systems, INC. | $69.82 | 2019 | |
| Chiesi USA, INC. | $65.00 | 2024 | |
| Biogen, INC. | $32.99 | 2022 | |
| Amgen INC. | $29.82 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajat Dhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.